期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

人附睾蛋白4与CA125联合检测在卵巢癌中的诊断价值 被引量：11

暂未订购
导出
摘要 目的探讨血清人附睾蛋白4(HE4)与CA125在卵巢癌妇女中的诊断价值。方法采用电化学发光法检测184例卵巢癌患者血清标本HE4和CA125,以132例卵巢良性疾病和57例健康体检者作为对照组。结果 (1)HE4检测水平在绝经前后均为卵巢癌组高于健康对照组和良性疾病组(P<0.05),但健康对照组与良性疾病组比较差异无统计学意义(P>0.05)。而CA125的检测水平在三组的比较中差异均有统计学意义(P<0.05)。(2)单独检测CA125的阳性率为79.35%,HE4的阳性率为67.39%,而两者联合检测阳性率高达92.39%,差异有统计学意义(P<0.05)。(3)Fisher判别分析表明对卵巢癌绝经前组与绝经后组联合检测HE4与CA125一致性较高,正确率分别为绝经前组78.82%(67/85),绝经后组79.80%(79/99)。结论 CA125对卵巢良恶性疾病的区分不如HE4好,联合检测血清HE4与CA125对卵巢癌的诊断价值更高。
作者 霍怡杉 黄艳春 王飞
机构地区 新疆医科大学附属肿瘤医院检验科
出处 《检验医学与临床》 CAS 2014年第1期68-70,共3页 Laboratory Medicine and Clinic
基金 新疆医科大学科研创新基金(xjc201272)
关键词 卵巢癌 人附睾蛋白4 CA125
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Drapkin R,Hecht JL. The origins of ovarian cancer: hurdles and progress[J]. Women Oncol Rev,2002,2(2) :261- 268.
  • 2范玉平,陶国华.联合检测HE4和CA125对卵巢癌早期评估的价值[J].标记免疫分析与临床,2010,17(6):368-371. 被引量：12
  • 3Moore RG,Mcmeekin DS,Brown AK,et al. A novel mul- tiplemaker bioassay utilizing HE4 and CA125 for the pre- diction of ovarian cancer in patients with a pelvic mass[J]. Gynecol Oncol,2009,112(1):40-46.
  • 4Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4(WFDC2)Protein is a Bimoarker for ovarian cacinoma[J]. Cancer Res, 2003,63 ( 13 ) : 3695-3700.
  • 5董丽,昌晓红,叶雪,朱丽荣,赵旸,田莉,程洪艳,李小平,张虹,廖秦平,付天云,成夜霞,崔恒.血清人附睾分泌蛋白4和CA125水平检测在卵巢恶性肿瘤中的诊断价值[J].中华妇产科杂志,2008,43(12):931-936. 被引量：98
  • 6Best RC Jr,Badgwell D,Lu Z,et al. New tummor markers CA125 and beyond[J]. Int J Gyneeol Cancer, 2005, 15 (3): 274-281.
  • 7陈观娣,李志刚,钱德英,毕燕玲,欧阳云雁.人附睾分泌蛋白在盆腔肿物中的诊断价值[J].实用医学杂志,2010,26(15):2774-2776. 被引量：14
  • 8Kirchhoff C, Habben I,Ivell R,et al. A major human epi- didymisspecific cdna encodes a protein with sequence ho- mology to extracellular proteinase inhibitors[J]. Biol Re- prod, 1991,45 (2) : 350-357.
  • 9Schummer M,Ng WV, Bumgarner RE, et al. Comparative hybridization of an array of 21500 ovarian cDNA for the discovery of genes over expressde in ocarfan carinomas [J]. Gene,1999,228(2),375-385.
  • 10Galgano MT, Hampton GM,Frierson HF Jr. Comprehen- sive analysis of HE4 expression in normal and malignant human tissues[J]. Mod Pathol, 2006,19 (6) .. 847-853.

二级参考文献29

  • 1杨永彬,徐伟,陈建利,万小平.卵巢癌肿瘤标志物研究进展[J].国外医学（妇产科学分册）,2004,31(4):229-232. 被引量：24
  • 2Gadducci A, Cosio S, Carpi A, et al. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother,2004,58 : 24 -38.
  • 3Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer,2000,82 : 1535-1538.
  • 4Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res, 2003,63 : 3695 -3700.
  • 5Israeli O, Goldring-Aviram A, Rienstein S, et al. In sihco chromosomal clustering of genes displaying altered expression patterns in ovarian cancer. Cancer Genet Cytogenet,2005 ,160 :35- 42.
  • 6Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 ( HE4 ) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res, 2005, 65:2162-2169.
  • 7Kirchhoff C, Habben I, Ivell R, et al. A major human epididymisspecific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod, 1991,45: 350- 357.
  • 8Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol,2008,108:402-408.
  • 9Schink J C.Current initial therapy of stage Ⅲ and Ⅳ ovarian cancer:chanllenges for managed care[J].Sem Oncol Feb,1999,26(1 Suppl):2-7.
  • 10Fishman D A,Bozorgi K.The scientific basis of early detection of epithelial ovarian cancer early detection program(NOCEDP)[M] //Stack M S,Fishman D A.Ovarian cancer.Boston:Kluwer Academic Publishers,2002:3-28.

共引文献117

同被引文献81

  • 1崔美兰,王庆一,赵春平,杨文娟.HE4、CA125和CA72-4联合检测对卵巢恶性肿瘤的诊断价值[J].中国老年学杂志,2014,34(3):614-615. 被引量：7
  • 2张欣,吴令英,李晓江,李洪君,张蓉,刘丽影.盆腔良性肿物伴血清CA_(125)水平升高的临床意义[J].中华妇产科杂志,2005,40(3):178-182. 被引量：65
  • 3廖琪,马晓艳.联合检测CA125、CA72-4和TSGF在卵巢癌诊断中的价值[J].中国医师杂志,2007,9(2):257-258. 被引量：3
  • 4Koprow H, Hedyn M, Steplew H, et al. Specific antigen in Serum of pa- tients with colon carcinoma [ J ]. Science ,2010,212:53 - 59.
  • 5Jakimovska M, Ceme K. Circulating serum sVCAM-1 concentration in advanced ovarian cancer patients : correlation with concentration in asci- tes[ J]. Radiol Oneol,2014,48(3 ) :307 - 313.
  • 6Donach M, Yu Y, Artioli G, et al . Combined use of biomark ers for detection of ovarian cancer in high-risk women[J]. Tumor Biol, 2010,31(3) :209-215.
  • 7Donach M, Yu Y, Artioli G, et al. Combined use of biomarkers for detection of ovarian cancer in high-risk women [J]. Tumor Biol, 2010, 31(3): 209-215.
  • 8Medeiros LR, Rosa DD, da Rosa MI, et al. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review [J] . Eur J Obstet Gynecol Reprod Biol, 2009, 142 (2) : 99-105.
  • 9Gu P, Pan LL, Wu SQ, et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis [J] . Eur JRadiol, 2009, 71 (1) : 164-174.
  • 10Ferraro S, Schiumarini D, Panteghini M. Human epididymis protein 4: factors of variation [J] . Clin Chim Aata, 2015, (438) : 171-177.

引证文献11

二级引证文献61

检验医学与临床
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部